Page last updated: 2024-09-03

marimastat and Adenocarcinoma

marimastat has been researched along with Adenocarcinoma in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	6 (75.00)	29.6817
2010's	1 (12.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Haage, A; Schneider, IC	1
Abbruzzese, JL; McConkey, D; Pino, SM; Xiong, HQ	1
Davis, TR; Hutchinson, JW; Parsons, SL; Tierney, GM	1
Bowry, C; Bramhall, SR; Brown, PD; Buckels, JA; Rosemurgy, A	1
Brown, P; Buckels, J; Carmichael, J; Daniel, F; Evans, JD; Imrie, CW; Johnson, CD; Neoptolemos, JP; Stark, A	1
Wolff, RA	1
Baillet, M; Bramhall, SR; Brown, PD; Fielding, JW; Hallissey, MT; Hawkins, RE; Maughan, T; McCulloch, P; Scholefield, J; Stuart, RC; Tierney, G; Whiting, J	1
Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J	1

Reviews

2 review(s) available for marimastat and Adenocarcinoma

Article	Year
Novel therapies for pancreatic adenocarcinoma. Current gastroenterology reports, 2004, Volume: 6, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense	2004
Exploiting molecular targets in pancreatic cancer. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:1 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Cycle Proteins; Cetuximab; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Research Design; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Suppressor Protein p53	2002

Article

Year

Novel therapies for pancreatic adenocarcinoma.

Current gastroenterology reports, 2004, Volume: 6, Issue:2

Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense

2004

Exploiting molecular targets in pancreatic cancer.

Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:1

Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Cycle Proteins; Cetuximab; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Research Design; Signal Transduction; TOR Serine-Threonine Kinases; Trastuzumab; Tumor Suppressor Protein p53

2002

Trials

4 trial(s) available for marimastat and Adenocarcinoma

Article	Year
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-01, Volume: 19, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Hydroxamic Acids; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate	2001
A phase II trial of marimastat in advanced pancreatic cancer. British journal of cancer, 2001, Dec-14, Volume: 85, Issue:12 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-19-9 Antigen; Female; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Life Tables; Male; Metalloendopeptidases; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Neoplasm Staging; Pain; Palliative Care; Pancreatic Neoplasms; Pilot Projects; Protease Inhibitors; Quality of Life; Survival Analysis; Treatment Outcome	2001
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; L-Lactate Dehydrogenase; Male; Metalloendopeptidases; Middle Aged; Safety; Stomach Neoplasms; Survival Rate; Tissue Distribution; Treatment Outcome	2002
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. British journal of cancer, 2002, Jul-15, Volume: 87, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis	2002

Other Studies

2 other study(ies) available for marimastat and Adenocarcinoma

Article	Year
Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014, Volume: 28, Issue:8 Topics: Adenocarcinoma; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Collagen; Elasticity; Extracellular Matrix; Gels; Heparan Sulfate Proteoglycans; Heparin Lyase; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Recombinant Proteins	2014
Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. The Journal of bone and joint surgery. British volume, 1998, Volume: 80, Issue:5 Topics: Adenocarcinoma; Bursitis; Dupuytren Contracture; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Stomach Neoplasms	1998

Article

Year

Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2014, Volume: 28, Issue:8

Topics: Adenocarcinoma; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Shape; Collagen; Elasticity; Extracellular Matrix; Gels; Heparan Sulfate Proteoglycans; Heparin Lyase; Humans; Hydroxamic Acids; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Recombinant Proteins

2014

Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor.

The Journal of bone and joint surgery. British volume, 1998, Volume: 80, Issue:5

Topics: Adenocarcinoma; Bursitis; Dupuytren Contracture; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Stomach Neoplasms

1998